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Type 2 diabetes (T2D) had long been referred to as the ‘‘geneticist’s nightmare.’’ Genome-wide association
studies have fully confirmed the polygenic nature of T2D, demonstrating the role of many genes in T2D risk.
The increasingly busier picture of T2D genetics is quite difficult to understand for the diabetes research com-
munity, which can create misunderstandings with geneticists, and can eventually limit both basic research
and translational outcomes of these genetic discoveries. The present review wishes to lift the fog around ge-
netics of T2D with the hope that it will foster integrated diabetes modeling approaches from genetic defects
to personalized medicine.Introduction: Is Type 2 Diabetes a Genetic Disorder?
According to the World Health Organization (WHO), approxi-
mately 350 million people worldwide have diabetes, and this
disorder is likely to be the seventh leading cause of death in
2030. Diabetes is an economic burden on healthcare systems,
especially in developing countries (World Health Organization,
2013).
Type 2 diabetes (T2D) emerged in the early 70s and was sepa-
rated from type 1 diabetes (T1D) thanks to the identification of
the role of the major histocompatibility complex in the auto-im-
mune process central to T1D pathogenesis (Bottazzo et al.,
1974). T2D, which currently accounts for 90% of all diabetic
patients, was called non-insulin-dependent diabetes or adult-
onset diabetes in the US (American Diabetes Association,
2013), and fat diabetes (diabe`te gras) in France, as overweight
and unhealthy lifestyles were considered at that time its only trig-
gers (Pirart, 1959). In the 80s, the scientific community started to
speculate about the strong familial clustering of T2D (Zimmet,
1982), but also about the extreme difficulty underlying its genetic
basis. T2D had long been referred to as the geneticist’s night-
mare (Neel, 1976). In 1985, a WHO study group suggested that
T2D might be an autosomal dominant disorder involving only
one dominant gene and characterized by a variable penetrance
dependent on both obesity and aging (Vftter, 1986). The first
evidence that T2D may be genetically driven was only brought
in 1992, through familial linkage analysis of French pedigrees
with early-onset, non-auto-immune, non-obese diabetes that
was also called maturity-onset diabetes of the young (MODY)
(Froguel et al., 1992). Mutations in GCK (encoding glucokinase)
were shown to cause a relatively benign form of MODY. Inciden-
tally, it was the first time that the direct causative effect of rela-
tive insulin deficiency was demonstrated in T2D, when insulin
resistance was believed to be the only trigger. The subsequent
identification of 28 distinct genes harboring mutations causing
monogenic diabetes has brought groundbreaking insights on
diabetes physiology, especially on insulin secretion, but theyonly affect less than 5% of diabetic patients (Shields et al.,
2010) (Figure 1).
Common T2D is actually a complex multifactorial polygenic
disease, which results from many different genetic events that
can interact together and with environmental factors. In other
words, none of these numerous associated genetic variants
are penetrant enough to lead to T2D alone. Twin or family studies
showed that the estimates of the heritability of T2D range from 30
to 70%, depending on the age of diabetes onset and the glyce-
mic status of cases (Almgren et al., 2011; Poulsen et al., 1999).
These studies suggested a greater role of genetics in the first
phases of development of T2D and a greater contribution of
the environment to T2D risk in older patients, which was
observed in other complex polygenic disorders like myocardial
infarction (Rosamond et al., 2008).
Several recent studies, including genome-wide association
studies (GWAS; see below), have fully confirmed the polygenic
nature of T2D and demonstrated themodest, but true, role of ge-
netic regions in T2D risk. The tangled picture of T2D genetics is
difficult to understand for the diabetes research community,
which creates misunderstandings with geneticists, and eventu-
ally limits both basic research and translational outcomes of
these genetic discoveries. The present review aims to brighten
the genetics of T2D so as to encourage integrated T2Dmodeling
approaches from genetic defects to personalized medicine.
The Contribution of Frequent Genetic Variants to
Common T2D Risk
Family Linkage Studies: No Major Gene in Common T2D
In contrast to GWAS mainly based on the comparison of unre-
lated cases and controls (see below), linkage studies looked
for co-segregation between genetic markers and disease in
multiplex pedigrees. Parametric analyses were very powerful
when the mode of inheritance was well known, while non-para-
metric statistics were more liberal in their a priori mode of trans-
mission assumptions. The hypothesis behind familial linkage inCell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc. 357
Figure 1. List of Genes Known to Harbor Mutations Causing
Monogenic Forms of Diabetes: Neonatal Diabetes and/or MODY/
Familial Early-Onset Diabetes
Underlined genes are also known to harbor common SNPs contributing to
common T2D. MODY, maturity-onset diabetes of the young. *This gene has
been found to harbor a rare (and not frequent) mutation associated with
common T2D. **This gene has been found to harbor common SNPs associ-
ated with fasting glucose levels.
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enough to cause disease under certain circumstances. Although
the community put a great deal of effort into genome-wide
familial linkage studies during 10 years, only a few T2D putative
linked regions were identified through this strategy: CAPN10
(Hanis et al., 1996), ADIPOQ (Vionnet et al., 2000), HNF4A (Si-
lander et al., 2004), ENPP1 (Meyre et al., 2005), and TCF7L2
(Grant et al., 2006). Yet, only the associations of HNF4A and
TCF7L2 loci with T2D risk were subsequently replicated by
GWAS analyses, casting doubt about the contribution of the
others (Figure 2) (Kooner et al., 2011; Sladek et al., 2007). Impor-
tantly, the hypothesis of major genes involved in common T2D
has not been demonstrated, as even HNF4A and TCF7L2 single
nucleotide polymorphisms (SNPs) were unable to explain the
observed linkage.
The only big success of the pre-GWAS era was the identifica-
tion of TCF7L2 as a T2D-susceptibility gene. A common intronic
SNPwithin TCF7L2 has been repeatedly demonstrated to confer
the strongest effect on T2D risk discovered so far, with an odds
ratio (OR) roughly 1.50 (Grant et al., 2006). TCF7L2 encodes a
transcription factor involved in the Wnt signaling pathway, which
is expressed in many tissues, including those with a key meta-
bolic role (Nobrega, 2013). Though various cell or animal studies
reported compelling evidence for a strong involvement of
TCF7L2 into pancreatic beta cell mechanisms including insulin
production and processing (Zhou et al., 2014), some reports
also raised the possibility that the beta cell dysfunction related
to TCF7L2was indirect andwas instead the consequence of dis-
ruptions in liver, brain, or gut (Boj et al., 2012; Shao et al., 2013). It358 Cell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc.remains that, in humans, the T2D risk allele in TCF7L2 is mark-
edly associated with a pancreatic phenotype evoking a primary
islet dysfunction, and not with insulin resistance or with liver ab-
normalities (Saxena et al., 2010).
Candidate Genes: Too Much Noise for Very Few
Advances
In the last 20 years, a plethora of biological candidate genes for
T2D were reported to harbor common SNPs nominally associ-
ated with T2D risk. However, GWAS (that should be considered
as the gold standard for common SNPs analyses) identified
association signals that lie within only a few physiologically
compelling T2D genes: GCK (Ma¨rz et al., 2004; Stone et al.,
1996), HNF1B (Winckler et al., 2007), WFS1 (Sandhu et al.,
2007), KCNJ11 (Hani et al., 1998), PPARG (Deeb et al., 1998),
and IRS1 (Almind et al., 1993) (Figure 2).
The studies of a putative role of frequent SNPs within GCK,
HNF1B, and WFS1 for common T2D logically followed the
identification of the genetic etiology of monogenic forms of dia-
betes, including MODY-2, MODY-5, and theWolfram syndrome,
respectively (Figure 1). Interestingly, although homozygous
WFS1 mutations in consanguineous families cause the Wolfram
syndrome (Inoue et al., 1998), it has been shown recently that
rare heterozygousWFS1 mutations can also lead to dominantly
inherited isolated adult-onset T2D (Figure 1) (Bonnycastle et al.,
2013). Therefore, there is a gradient of clinical severity depend-
ing on the functional effect and the state of deleteriousmutations
(i.e., homozygous or heterozygous) inWFS1, something that has
also been found in other genes involved in monogenic diabetes,
including GCK, PDX1, and NEUROD1 (Vaxillaire et al., 2012).
The assessment of the susceptibility of KCNJ11, PPARG, and
IRS1 to T2D was based on their known involvement into pancre-
atic beta cell function or insulin resistance. KCNJ11 encodes the
pore-forming subunit KIR6.2 of the ATP-dependent potassium
channel in pancreatic beta cells, which plays a pivotal role in in-
sulin granule exocytosis (Hani et al., 1998). Rare heterozygous
mutations in this genewere subsequently shown to causemono-
genic neonatal diabetes mellitus (Gloyn et al., 2004) as well as
MODY-13 (Bonnefond et al., 2012a) (Figure 1). PPARG encodes
the nuclear receptor PPAR-g, which plays a crucial role in adipo-
cyte differentiation and function and is a well-known molecular
target for thiazolidinedione insulin sensitizer to treat T2D (Deeb
et al., 1998). Deleterious heterozygous dominant-negative muta-
tions in PPARG were shown to cause monogenic severe insulin
resistance with lypodystrophy and liver disease progressing to
T2D at an early age (Barroso et al., 1999). IRS1 encodes the in-
sulin receptor substrate-1 that is necessary for insulin action in
insulin-sensitive tissues and pancreatic beta cells (Almind
et al., 1993). IRS1 has been the only success story of an obvious
candidate gene that was not responsible for monogenic dia-
betes too. However, the initial T2D-associated coding mutation
in IRS1 was not subsequently confirmed by GWAS, as the
GWAS signal was actually located adjacent to the gene (Rung
et al., 2009).
GWAS Legacy to T2D Research
Since GWAS were chosen as a Breakthrough of the Year 2007
by Science, they have generated many enthusiastic commen-
taries followed by excessive criticisms. Obviously, GWAS have
brought groundbreaking advances in the genetics of common
T2D, which was still poorly elucidated in the mid-2000s. This
Figure 2. List of Loci Known to Harbor Common SNPs Contributing to Common T2D
Underlined loci are also known to harbor rare mutations causingmonogenic forms of diabetes. Technologies used for the identification of T2D-suceptibility genes
are shown below the figure. The T2D-related functions of genes have been set according to several publications (Mahajan et al., 2014; Dimas et al., 2014; Marullo
et al., 2014; Moltke et al., 2014; Pasquali et al., 2014; Vassy et al., 2014). Moreover, T2D-suceptibility genes that are known to harbor rare mutations causing
monogenic forms of diabetes have been classified according to their known function. The ethnicity of the population originally analyzed is also shown for each
T2D-susceptibility gene. AA, African American; CE, Caucasian European; EA, East Asian; G, Greenlandic; GWAS, genome-wide association study; M, Mexican;
SA, South Asian; T2D, type 2 diabetes; TA, trans-ancestry; WES, whole-exome sequencing.
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ect, subsequently exploited by HapMap for the identification
and selection of tagSNPs, by a marked technological advance
in the throughput for SNP genotyping through extremely reliable
and inexpensive DNA microarray technology, and by robust sta-
tistical analyses enabling the careful assessment of hundreds of
thousands of common SNPs in a large sample size of T2D cases
and controls. Importantly, GWAS identifies disease-associated
SNPs, which are conveniently named by the nearest genes;
thus, it does not necessarily implicate the genes as causal.
The first T2D GWAS that analyzed normal-weight T2D individ-
uals and normoglycemic controls of European origin demon-
strated the leading contribution of TCF7L2 to T2D and reported
three new T2D-susceptibility genes: SLC30A8 and HHEX, which
were subsequently confirmed (Figure 2), and EXT2-ALX4, which
has not been replicated (Sladek et al., 2007). This first study was
quickly followed by several other GWAS papers that confirmed
the previous data, and found new loci, most of them identified
through an innovative merging strategy of data from different
cohorts that was later named GWAS meta-analysis. The major
goal of these meta-analyses was to optimize the identification
of new signals by increasing the statistical power of the studies.This first wave of GWAS led to the identification of a dozen new
T2D-associated genes in Europeans: ADAMTS9, CDC123/
CAMK1D, CDKAL1, CDKN2A/B, IGF2BP2, JAZF1, NOTCH2,
RBMS1, THADA, and TSPAN8/LGR5 (Figure 2) (Saxena et al.,
2007; Qi et al., 2010; Scott et al., 2007; Zeggini et al., 2007,
2008).
In parallel, three independent studies found an obesity-sus-
ceptibility gene that was renamed FTO (fat mass and obesity-
associated protein) (Dina et al., 2007; Frayling et al., 2007;
Scuteri et al., 2007). Frayling et al. (2007) initially discovered an
association signal at FTOwith T2D that disappeared after adjust-
ment for BMI, suggesting an indirect effect of FTO on T2D risk,
which was actually mediated by the excess of adiposity.
Although all these GWAS were performed in unrelated individ-
uals, an Icelandic GWAS took into account the parental origin of
transmitted alleles and identified a new T2D association signal in
MOB2 (Kong et al., 2009) (Figure 2).
A second wave of GWAS papers came from the linear anal-
ysis of T2D-related metabolic quantitative traits in non-diabetic
individuals, which opposed the logistic analyses in T2D cases
and controls. This strategy indirectly identified five new T2D-
associated genes in Europeans: MTNR1B, DGKB, PROX1, andCell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc. 359
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variation of fasting glucose levels (Bouatia-Naji et al., 2009; Du-
puis et al., 2010; Prokopenko et al., 2009), andGCKR, which was
primarily found to be associated with the variation of fasting
glucose levels, fasting insulin levels, and triglyceride levels (Sax-
ena et al., 2007; Dupuis et al., 2010) (Figure 2). Interestingly, the
overlap between loci influencing glucose- or insulin-related traits
and T2D-susceptibility loci was unexpectedly limited (Dupuis
et al., 2010). This result suggests that genes and related path-
ways that influence normal physiological levels of metabolic
traits can be different from those leading to pathophysiological
levels of metabolic traits that define T2D. A recent study
strengthened this conclusion showing that the combination of
established SNPs raising fasting glucose levels was significantly
associated with the incidence of impaired fasting glucose levels
over the 9-year follow-up of the study, but not with the risk of
developing overt T2D (Vaxillaire et al., 2014).
In 2010, a very largemeta-analysis includingmore than 50,000
participants found a dozen new T2D-susceptibility genes in Eu-
ropeans (Figure 2) (Voight et al., 2010). Further stratification of
T2D participants by BMI identified a new T2D association signal
in LAMA1 (Figure 2): a SNP at this locus associated with T2D risk
in lean cases only (Perry et al., 2012).
In parallel, GWAS and meta-analyses of GWAS were per-
formed in other ethnicities (i.e., East Asians, South Asians, Afri-
can Americans) and generated multiple new T2D-associated
genes (Figure 2) (Cho et al., 2012; Hanson et al., 2014; Kooner
et al., 2011; Li et al., 2013; Ma et al., 2013; Palmer et al., 2012;
Saxena et al., 2013; Shu et al., 2010; Tabassum et al., 2013;
Tsai et al., 2010; Unoki et al., 2008; Yamauchi et al., 2010; Ya-
suda et al., 2008).
Thesemeta-analyses have been limited by the fact that at best
the last generation of SNP microarrays analyzes a few million
common SNPs from more than 30 million SNPs discovered so
far. To overcome this issue, GWAS data were imputed using
whole-genome sequencing (WGS) data, mostly from the recent
releases of HapMap or 1000 Genomes project (1000G). This
strategy also allows the geneticists to fine-map established as-
sociations and identify the putatively causative SNPs from all
SNPs that are present in a given associated DNA region to in-
crease the power and/or to provide a uniform catalog of analyzed
SNPs across studies within large meta-analyses. This strategy
led to the identification of six new T2D susceptibility genes in
Japanese individuals (Hara et al., 2014), in Mexicans and other
Latin Americans (Williams et al., 2014), and in African Americans
(Ng et al., 2014) (Figure 2). Lastly, several consortia performed
a genome-wide trans-ancestry meta-analysis including more
than 110,000 participants of various ancestries so as to boost
the power and to improve the fine-mapping resolution of causal
variants (Mahajan et al., 2014). Here, the imputation was manda-
tory to homogenize each set of SNPs between cohorts of
different ancestry. They found seven new T2D susceptibility
genes (Figure 2).
Finally, special inexpensive DNA microarrays have also been
instrumental in finding additional T2D-associated genes. The
Metabochip custom genotyping arrays were designed to follow
up nominal (i.e., non-genome-wide significant) signals associ-
ated with cardiometabolic traits and associated diseases or to
fine-map well-established associations (Voight et al., 2012).360 Cell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc.This staged approach led to the identification of 11 new T2D-
susceptibility genes in Europeans (Morris et al., 2012) and
in the Greenland population (Moltke et al., 2014) (Figure 2).
Paradoxically, only half of the new signals were present in the
Metabochip due to their originally nominal association with
T2D (ANK1, BCAR1, CCND2, TLE1, and ZMIZ1); the others
were initially associated with postprandial glucose levels during
an oral glucose tolerance test (GIPR), glycated hemoglobin
A1c (KLHDC5), blood pressure (ANKRD55), lipids (CILP2),
BMI (MC4R), and waist-to-hip ratio (TBC1D4). These findings
confirmed the high complexity of T2D genetic architecture and
the pleiotropic effect of associated genes. Illumina has recently
launched an exome array that consists of 250,000 common
and much rarer SNPs located in exonic regions that were found
in genetic studies on a range of diseases including cardiometa-
bolic disorders. This new beadchip will probably soon extend the
list of T2D genes.
NGS, the Next-Generation Genetic Studies in T2D
Since 2009, the development of next-generation sequencing
(NGS) has revolutionized the fields of genetics and genomics in
many ways. NGS studies, mainly of exomes at this time, have
brought insights in several rare Mendelian disorders, including
neonatal diabetes and MODY (Bamshad et al., 2011), and a
substantial number of NGS studies have pointed out additional
association signals. In T2D, a first multi-stage study primarily
driven by low-coverage whole-exome sequencing (WES) in
2,000 Danes highlighted two coding SNPs significantly associ-
ated with T2D located in two new genes (Figure 2) (Albrechtsen
et al., 2013). In the near future, by boosting the statistical power
of NGS studies through the merge of multiple WES cohort data
sets, international consortia have the potential to identify new
T2D susceptibility exonic mutations with a putatively marked
impact on coded protein function.
Do the Genetics of Common T2D Illuminate T2D
Pathophysiology?
Despite the dramatic success of GWAS and GWAS meta-ana-
lyses (Figure 2), there is a substantial gap between the discovery
of many T2D-associated SNPs and the understanding of how
these SNPs physiologically impact T2D pathogenesis. So far,
80% of all T2D-associated SNPs are intergenic or intronic, and
the geneticists have named the closest gene on the SNP chro-
mosome as the T2D-susceptibility gene without having strong
clues about the molecular link between the gene and the variant.
An associated SNP can actually interact with a distant gene
located on the same chromosome, as suggested for the
obesity-associated SNPs in FTO, which would actually impact
IRX3 (Ragvin et al., 2010; Smemo et al., 2014), or even located
elsewhere in the genome.Worst, it may have no functional effect,
as it only tags a linkage disequilibrium (LD) block (i.e., a DNA re-
gion transmitted together from one generation to the next one).
Furthermore, the individual effect of these SNPs on T2D risk is
typically modest; namely, each risk allele usually increases less
than 15% the risk of developing T2D (OR < 1.15). As a conse-
quence, all common T2D-associated SNPs have captured less
than 15% of T2D familial aggregation (Morris et al., 2012).
Furthermore, this has important consequences for experimental
studies: it is unlikely that any of the frequent DNA mutations
found to associate with polygenic T2D through GWAS are suffi-
cient to cause a major phenotype in diabetes models, as the
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casionally, the mechanisms that causally link a common T2D-
associated SNP to a gene and to T2D have been elucidated.
For instance, an elegant study has identified clusters of active
enhancers targeted by major human islet transcription fac-
tors, using a combination of formaldehyde-assisted isolation of
regulatory elements (FAIRE) technique and chromatin immuno-
precipitation (ChIP), both coupled with NGS (FAIRE-seq and
ChIP-seq, respectively) (Pasquali et al., 2014). The authors
demonstrated that these chromosome regions serving as super
enhancers of the islet genome expression carry a large load of
T2D-associated SNPs, pointing out the impact of these SNPs
on islet functions. In particular, SNPs in or nearby TCF7L2,
ZFAND3, CDKN2A, C2CD4A, C2CD4B, SLC30A8, and DGKB
were shown to disrupt DNA binding and islet enhancer activity
(Pasquali et al., 2014).
The predominance of T2D-associated genes presumably con-
trolling pancreatic islet and beta cell function is supported by
purely genetic epidemiology studies too. Indeed, the impact of
known T2D-SNPs was shown to be markedly higher in normal-
weight T2D cases compared to obese T2D cases (Cauchi
et al., 2008; Perry et al., 2012). These findings emphasized that
many T2D-associated SNPswith strong genetic contribution pri-
marily affect pancreatic beta cell function. Furthermore, the
extensive work done by the Meta-Analyses of Glucose and Insu-
lin-related traits Consortium (MAGIC) using biological traits (e.g.,
glucose, insulin, or proinsulin levels) as quantitative traits allowed
the partitioning of T2D-associated SNPs according to the puta-
tive effect of the T2D risk allele on beta cell function or insulin
resistance in non-diabetic individuals (Dimas et al., 2014).
From these studies, more than 30% of T2D-associated SNPs
are likely to affect insulin secretion or beta cell function, while
15%of theseSNPsmay play a role in insulin resistance (Figure 2).
A recent elegant study showed that the combination of SNPs
that impact beta cell function significantly predicted incident
T2D, but not the combination of SNPs contributing to insulin
resistance (Vassy et al., 2014). The mechanisms by which the
remaining T2D-associated SNPs (i.e., more than half of the
T2D-associated SNPs) affect disease pathogenesis have not
been determined by genetic epidemiology studies, and further
functional studies are necessary.
Taking advantage of the quick and recent progress of NGS
tools, research groups have started studying the putative contri-
bution of rare coding variants, hoping to reveal a stronger effect
on the disease, with the goal to functionally investigate them
and draw clear conclusions on the mutations, the genes, and
the disease.
The Contribution of Rare or Low-Frequency Genetic
Variants to Common T2D
Niche of T2D-Associated Rare Variants in GWAS-
Identified T2D Genes
As said above, association does not mean causality. The
identification of true associations between SNPs within or
nearby genes and T2D does not necessarily imply that these
SNPs or other variants in the same regions have a direct etio-
logical effect on T2D. Furthermore, GWAS results can some-
times be totally misleading, as shown for the genetic link be-
tween HK1 (encoding hexokinase 1) and glycated hemoglobinA1c: although HK1 locus showed the strongest association
with this marker of glucose control, a more careful analysis re-
vealed that HK1 association signal was unrelated to glucose
homeostasis, but instead involved in blood red cell function
(Bonnefond et al., 2009). The association with glycated hemo-
globin A1c was genuine, though the initial explanation linking
this enzyme with T2D was later proven wrong. A way to estab-
lish causality beyond GWAS is to identify rare coding mutations
in the gene located nearby the most associated SNP, which
clearly impairs protein function and modulates T2D pathophys-
iology. Notably, the genetic field arbitrarily defines variants with
a frequency below 1% as rare, while low-frequency variants
have a frequency of 1%–5%, and frequent SNPs have a minor
allele frequency (MAF) above 5%.
In 2012, a causal link was demonstrated between T2D risk and
the dysfunction of the melatonin receptor 1B (MTNR1B) due to
rare loss-of-function variants (Figure 3). MTNR1B encodes a
Gai-protein-coupled receptor (GPCR) and may be a promising
drug target. The study combined large-scale MTNR1B rese-
quencing with a systematic four-tier cell-based investigation of
each identified mutation, followed by a replication step of the
mutations with the most deleterious effect in additional individ-
uals (Figure 4) (Bonnefond et al., 2012b). The two coding exons
of MTNR1B were sequenced in 7,632 Europeans, including
2,186 T2D individuals. 40 non-synonymous mutations were
identified, including 36 very rare mutations with a frequency
below 0.1%, which were strongly associated with increased
T2D risk (with an OR of 3.31), while the mutations with a fre-
quency above 0.1% did not significantly contribute to T2D (Bon-
nefond et al., 2012b). The 40mutations were then investigated at
four levels in human cell lines: four mutants were unable to bind
melatonin and to activate downstream pathways, while 10 other
mutants were unable to stimulate ERK phosphorylation or acti-
vate Gi protein in the presence of melatonin (Figure 5) (Bonne-
fond et al., 2012b). The aggregation of these loss-of-function
variants with a frequency below 0.1% yielded a T2D risk
increased by greater than 5.5-fold, while the neutral very rare
variants did not have any effect on T2D (Bonnefond et al.,
2012b). This study is important as it established a mechanistic
link between the presence of human mutations in a GWAS-iden-
tified gene and T2D risk. Since melatonin is a neurohormone that
modulates circadian rhythms in the body in response to daylight,
this study implies that melatonin receptor agonists, already pre-
scribed for depression and sleep disorders, may be useful for
T2D treatment (Bonnefond et al., 2012b).
More recently, and using the same kind of strategy (without a
final replication step, however) (Figure 4), a study demonstrated
that rare loss-of-function variants in the nuclear receptor en-
coded by PPARG increased T2D risk (Figure 3) (Majithia et al.,
2014). Coding exons of PPARG were sequenced in 20,000
multiethnic T2D cases/control samples as part of several candi-
date gene sequencing or WES studies including several consor-
tia (Majithia et al., 2014). The authors identified a total of 52
rare non-synonymous PPARG variants that were not associated
with T2D, even after variant stratification according to the
in silico prediction of their putative functional effect (Majithia
et al., 2014). Through high-throughput assays allowing the quan-
tification of adipocyte differentiation in response to each exoge-
nous PPAR-g mutant, the authors found that only 12 mutationsCell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc. 361
Figure 3. Distribution of Both Effect Size and Frequency of Variants/Mutations Contributing to Monogenic Forms of Diabetes or to
Common T2D
The effect size of genetic variants in diabetes-associated genes is reported on the x axis, while the frequency of these variants is reported on the y axis. The arrows
show the technologies/experiments used for the identification of causal or associated variants in each group of variants (purple, rare variants involved in
monogenic diabetes; orange, rare or low-frequency variants involved in common T2D; green, frequent SNPs involved in common T2D). The rectangles show the
number or the name of genes that carry rare variants involved inmonogenic diabetes (purple), rare or low-frequency variants involved in common T2D (orange), or
frequent SNPs involved in common T2D (green). MODY, maturity-onset diabetes of the young; ND, neonatal diabetes; NGS, next-generation sequencing; SNP,
single nucleotide polymorphism; T2D, type 2 diabetes.
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which significantly yielded in aggregation an increased T2D risk
of greater than 7-fold, while the combined neutral variants did
not have any effect on T2D (Majithia et al., 2014). The carriers
of loss-of-function variants in PPARG did not present with
extreme insulin resistance phenotypes (Majithia et al., 2014),
as originally observed in families with severe lipodystrophy
(Barroso et al., 1999), although three of these deleterious vari-
ants had already been reported in such families. Therefore, the
penetrance and the phenotypic expressivity of loss-of-function
PPARG mutations are variable.
Another GWAS-identified T2D gene was found to harbor rare
mutations associated with T2D: SLC30A8 (Figure 3) (Flannick
et al., 2014). SLC30A8 encodes a zinc transporter that is located
in the insulin granules in pancreatic beta cells. The study was pri-
marily driven by NGS targeting specifically 115 genes that lay
either within GWAS-identified T2D-associated loci or genes con-
taining rare mutations known to cause monogenic diabetes, in
758 Europeans. The authors pointed out a nonsense mutation
in SLC30A8, which was more present in controls than in individ-
uals with T2D (Flannick et al., 2014). As the p value of the protec-
tion of this mutation against T2D was only nominal, they sought
additional evidence through (1) the genotyping of this mutation
in 50,000 Europeans, which replicated the protection of
the nonsense variant against T2D; (2) WGS and imputation in
71,000 Icelanders, which identified a frameshift mutation that
was enriched in controls compared to T2D cases; (3) the
genotyping of this frameshift variant in 5,000 Norwegians, which
was only found in controls; (4) the functional assays, which362 Cell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc.showed that the overexpression of both nonsense and frame-
shift SLC30A8 mutants markedly decreased SLC30A8 expres-
sion; and (5) WES in 12,000 individuals from various ethnicities,
which identified 10 additional rare SLC30A8 variants that protect
against T2D when analyzed in aggregation. The meta-analysis
of all these studies showed a significant protection of rare
SLC30A8 variants against T2D with an OR of 0.34 (Flannick
et al., 2014). Unfortunately, the functional studies were only per-
formed for 2 out of 12 identified mutations. Additional functional
investigations of human variants in different models would be
useful to understand the precise molecular mechanisms of
SLC30A8 dysfunction underlying the unexpected protective
effects against T2D. Indeed, a recent comprehensive review
pointed out conflicting data from animal and cellular studies
on the zinc transporter SLC30A8 role in insulin secretion, and
more genetic studies would help to bring definite responses (Da-
vidson et al., 2014).
A study has recently identified a low-frequency loss-of-func-
tion variant in HNF1A encoding the homeodomain-containing
transcription factor HNF-1a, which strongly increased T2D risk
in Mexicans and Latin Americans (Figure 3) (Estrada et al.,
2014). Through WES in 3,756 individuals of Mexican origin,
the study found that the HNF1A missense variant (p.E508K,
with a frequency of 0.2% in controls) yielded an increased
T2D risk of about 5-fold. This result was replicated in more
than 3,000 Mexicans. Rare mutations in HNF1A had already
been known to cause MODY-3 (Figure 1) (Vaxillaire et al.,
1995). Here, the authors demonstrated that p.E508K mutation
impacted the HNF-1a transactivation activity, although to a
Figure 4. Typical Experimental Design to Draw a Causal Link between Rare Variants and T2D
This figure shows how a causal link can be established between rare variants and T2D. The first step is a large-scale resequencing of genes (or evenWES orWGS)
in cases and controls. The second step is to look for a significant enrichment in cases of rare variants in aggregation (in each gene). When a suggestive enrichment
of rare variants within a gene is identified in cases, the third step is the analysis of functional consequences of each variant using various models, so as to know
whether the functional variants (and not the neutral ones) are significantly enriched in cases. A final step of replication can be performed to confirm the association
of functional variants with disease risk in additional individuals. T2D, type 2 diabetes.
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Furthermore, compared with wild-type HNF-1a, the p.E508K
mutant equally bound to DNA, but its localization was not
bordered to the nucleus. The age at onset of T2D in the carriers
of p.E508K was similar in other T2D Mexican individuals. Impor-
tantly, this mutation had previously been reported in only two
MODY-3 European families (Bellanne´-Chantelot et al., 2008;
Forlani et al., 2010) and in one isolated T2D European patient
(Flannick et al., 2013). Therefore, this mutation seems very
rare but more penetrant in the European ethnicity. Similar strik-
ing ethnic contrast in mutation penetrance and expressivity was
previously observed for heterozygous MC4R mutations that are
less penetrant for obesity in Pakistan than in Europe (Saeed
et al., 2012). Importantly, the identification of HNF1A p.E508K
in T2D patients may have clinical implications toward personal-
ized diabetic medicine, as it has been evidenced that MODY-3
patients treated with oral sulfonylureas show a better glycemic
control when compared with those treated with insulin in the
long term (Shepherd et al., 2003), and they may be good re-
sponders to GLP-1 analogs (Østoft et al., 2014).
HNF1A is not the only gene harboring rare loss-of-function
mutations causing a spectrum of diabetes-related phenotypes.
Several mutations in INS, KCNJ11, or ABCC8 can cause
neonatal diabetes, MODY, common T2D, mild hyperglycemia,
or even associate with apparent normal glucose tolerance in in-
dividuals sharing the same allele (Bonnefond et al., 2012a; Meur
et al., 2010; Riveline et al., 2012). Most of these specific muta-
tions were proven to be deleterious. Indeed, diabetic carriers
of a mutation in KCNJ11 or ABCC8 (which encode subunits of
ATP-dependent potassium channel in pancreatic beta cells)
can optimally be treated with oral sulfonylureas (Pearson et al.,2006), and the switch from insulin to oral sulfonylureas in diabetic
carriers of these specific mutations able to cause a spectrum of
diabetes-related phenotypes was actually very successful (Bon-
nefond et al., 2012a; Riveline et al., 2012).
A lesson from genetic studies is that mutations that have been
found to cause monogenic diabetes are not totally penetrant. In
this respect, a study has reported that nearly 1% of the general
population carried rare nonsynonymous variants in a MODY
gene, which had been previously identified in MODY probands
or were likely to be deleterious according to in silico functional
prediction (Flannick et al., 2013). Actually, prediction algorithms
should always be considered with healthy skepticism, as they
often bring erroneous conclusions (Bonnefond et al., 2012b,
2013;Majithia et al., 2014). The identification of a rareMODYmu-
tation in a single patient with a putative MODY phenotype is not
sufficient to establish causality. Ideally the causal link should be
reached through the study of the whole MODY family, cell-based
or animal-based functional studies, or a successful switch from
insulin therapy to oral sulfonylureas in MODY patients with a mu-
tation in HNF1A, KCNJ11, or ABCC8. It would be erroneous to
underestimate the deleterious impact of true monogenic dia-
betes mutations, as they have been rarely detected in general
population studies that are usually poorly phenotyped. The
main conclusion is the lack of true clinical interest for sequencing
the genome of healthy individuals, apart from having catalogs of
human genetic diversity. Even if putative loss-of-function muta-
tions are found through NGS, there is no way to assess their
physiological relevance for the future of the healthy individual.
In contrast, generalizing NGS in patients with serious disorders,
including diabetes, is probably relevant for patients’ stratification
and for precision medicine.Cell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc. 363
Figure 5. Four-Tier Functional Investigation of Each Mutation Identified in MTNR1B
40 mutations were investigated at four levels in human cell lines: expression of each mutant at the cell membrane (green line), binding of the melatonin in each
mutant (purple squares), and melatonin-dependent activation of Gi protein (black crosses) or ERK (red triangles) pathway by each mutant. Black arrows indicate
total loss-of-function mutants (i.e., unable to bind the melatonin), while gray arrows indicate partial loss-of-function mutants (i.e., unable to activate downstream
pathways). The unit is arbitrary.
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Risk in Novel T2D Genes
Using WGS of 2,630 Icelanders and imputation into 11,000
cases and 267,000 controls of Icelandic origin, followed by
a replication step in Danish and Iranian T2D case-control sam-
ples, a study has identified low-frequency or rare variants
independently contributing to T2D risk in two novel common
T2D-susceptibility genes (CCND2, PAM) and in one MODY
gene (PDX1) (Figure 3) (Steinthorsdottir et al., 2014). In CCND2,
a low-frequency intronic variant significantly protected against
T2D (OR 0.5), increased insulin release from pancreatic beta
cells in nondiabetic participants, and was associated with
increased CCND2 expression in white blood cells and adipo-
cytes (Steinthorsdottir et al., 2014). CCND2 encodes cyclin D2
that regulates G1/S cell-cycle transition in multiple cell types
including pancreatic beta cells (Steinthorsdottir et al., 2014). In
PAM, one low-frequency and one rare missense variant were
shown to moderately increase T2D risk (OR < 1.5) (Steinthors-
dottir et al., 2014). The rare variant was also associated with
reduced insulin release from pancreatic beta cells (Steinthors-
dottir et al., 2014). PAM encodes peptidylglycine a-amidating
monooxygenase, which plays a crucial role in post-translational
modifications of multiple peptides. In PDX1, a rare frameshift
variant strongly increased risk of T2D (OR2.3) (Steinthorsdottir364 Cell Metabolism 21, March 3, 2015 ª2015 Elsevier Inc.et al., 2014). PDX1 encodes a transcription factor with a key role
in pancreatic beta cell development, and mutations in this gene
cause MODY-4 or neonatal diabetes associated with pancreatic
agenesis when mutations are homozygous (Figure 1) (Vaxillaire
et al., 2012). PDX1 enriches the list of genes that can harbor
rare mutations causing a spectrum of diabetes subtypes like
HNF1A, ABCC8, KCNJ11, PPARG, INS, andWFS1 (see above).
A limitation of this study, however, remains the lack of functional
experiments demonstrating the causality of these rare variants
(Steinthorsdottir et al., 2014).
Conclusions and Future Directions
GWAS and GWASmeta-analyses have by far been themost effi-
cient way to identify new T2D genes (Figure 2), but their predic-
tive value for future occurrence of T2D has been very limited
compared to classic risk factors such as obesity and fasting
glucose levels (Walford et al., 2014). Although it might be good
news that our genome does not fully dictate our future, the
knowledge of its specificities may help us to improve our health.
Early genetic studies showed that the higher risk for T2D
conferred by TCF7L2 variant can be reversed by lifestyle inter-
vention (Florez et al., 2006), opening avenues for strategies tar-
geted on genetically selected individuals with pre-diabetes.
TCF7L2 has also been shown to be associated with a lower
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Perspectiveefficiency of oral sulfonylureas in newly diagnosed T2D patients
(Pearson et al., 2007), but a more recent Danish study suggested
that in contrast to clinical markers, all known T2D-associated
variants do not significantly affect the time to prescription of
the first drug after disease onset (Hornbak et al., 2014). In other
words, frequent SNPs are not helpful to predict patients’ futures,
though the good use of genetic data may contribute to provide
better care to newly diagnosed T2D patients who are currently
all treated the same (with metformin).
To be fair, the T2D missing heritability may explain part of the
weak predictive power of current T2D SNPs. The ‘‘black matter’’
issue has raised much interest within geneticists. Many explana-
tions have been proposed, including the putative overestimation
of T2D heritability (Groop and Pociot, 2014). Genetic or epige-
netic mechanisms other than SNP or mutation may also
contribute to T2D genetic risk. For instance, constitutional chro-
mosome variations, called gene copy-number variants (CNVs)
have been found to significantly contribute to obesity risk (Falchi
et al., 2014; Walters et al., 2010), but not to T2D risk so far.
The biggest opportunity for T2D genetics may be in assisting
experimental biologists and physiologists to establish the most
important pathways that are causatively associated with T2D
in humans, so as to design efficient drug therapies. Functional
genomics tools should be systematically used to bring
clues about the biological role of newly discovered genes (Bon-
nefond et al., 2012b; Majithia et al., 2014) and also to validate
the impact of variants that are not all deleterious, as shown
above in contrast to generous algorithm predictions. The rapidly
emerging induced pluripotent stem cell (iPSC) biology opens
unexplored avenues in T2D modeling in the own patients’ cells
(or cells from controls with causal mutations introduced by
genome editing), which could be derived into pancreatic beta
cells, hepatocytes, adipocytes, or muscle cells (Inoue et al.,
2014). Notably, the use of iPSCs is expected to be very useful
in drug discovery and in clinical trials, enabling the assessment
of drug responsiveness in each patient (drug responders versus
non-responders) through the analysis of the drug efficiency on
iPSC-derived cells (Inoue et al., 2014).
T2D human genetics has other potentials; for instance, NGS
large screen for mutations in new putative drug targets can be
very helpful in validating them (for example, if causing insulin
secretion defects in beta cells) and in determining drugs side ef-
fect in humans carrying loss- or gain-of-function mutations. T2D
genetics has shown biologists the results of the experiments of
nature that have mutated genes and non-coding regions, with
direct effects on T2D risk. It revealed in human the role of key
pathways involved in glucose homeostasis, opening novel
therapeutic avenues. As modern genomics is not biased by prior
researchers’ hypotheses, but aims to assess all genome influ-
ences comprehensively, it brings unique integrated information
that deserves to be tested by experimental biologists in animal
models and cell lines. Biologists ought not to fear the plethora
of T2D genes. On the contrary, together with geneticists, they
should formulate innovative strategies for exploiting genetic dis-
coveries in order to answer the following question in humans:
among the numerous described metabolic pathways, what is
essential to glucose control? What is causing early diabetic ab-
normalities? And what should be targeted to prevent or even
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